Did Supernus Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SUPN
Portfolio Pulse from
Levi & Korsinsky is investigating Supernus Pharmaceuticals, Inc. for potential federal securities law violations after its Phase 2b study of SPN-820 failed to meet its primary endpoint.
March 13, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The investigation by Levi & Korsinsky into Supernus Pharmaceuticals for potential securities law violations is significant due to the failure of the SPN-820 study. This could lead to legal challenges and affect investor confidence, likely impacting the stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100